Frequency of Benzodiazepine Use twelve. 6 Percent in the United States
Frequency of Benzodiazepine Use twelve. 6 Percent in the United States
Overall, 12. 6 percent of U. S. adults report past-year benzodiazepine use, with improper use accounting for 17. 2 percent of overall use, according to a examine published online Dec. 17 in Psychiatric Services.
Donovan T. Maust, M. M., from the University of Michigan in Ann Arbor, and colleagues conducted a cross-sectional analysis of data from the 2015 and 2016 National Survey on Drug Use and Well being limited to adults older ≥18 years (86, 186 participants) and respondents credit reporting benzodiazepine use (10, 290 participants). The authors analyzed the prevalence of benzodiazepine use, including variation by age.
The researchers found that 30. 6 , 000, 000 adults (12. 6 percent) reported past-year benzodiazepine use: 10. 4 and 2. 2 percent as prescribed and misuse, respectively. General, misuse accounted for 18. 2 percent of use. The best recommended use was seen for adults age range 50 to 64 years (12. 9 percent). Wrong use was highest for those ages 18 to twenty-five years (5. 2 percent) and lowest for those aged ≥65 years (0. 6 percent).
There is a strong correlation for wrong use and abuse of or dependence on prescription opioids or stimulants with benzodiazepine misuse.
The most common type of misuse was misuse without a doctor prescribed, with the most frequent source being a friend or family member.
"Although clinicians should be mindful of the prospective for benzodiazepine misuse among patients with any degree of substance use, conclusions indicated that prescription opioid and stimulant use problems were most strongly associated with benzodiazepine misuse, inches the authors write.
Send inquiry online For more product information and prices
(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
After sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone Swiss
Email: sales@raw-pharmaceutical-materials.comTel: +86 592 5365887
WhatsApp: +86 189 6515 7632
Send inquiry online: